Abstract
DNA copy number alterations, including entire chromosomal changes and small interstitial DNA amplifications and deletions, characterize the development of cancer. These changes usually affect the expression of target genes and subsequently the function of the target proteins. Since the completion of the human genome project, the capacity to comprehensively analyze the human cancer genome has expanded significantly. Techniques such as digital karyotyping have been developed to allow for the detection of DNA copy number alterations in cancer at the whole-genome scale. When compared with conventional methods such as spectral karyotyping, representational difference analysis, comparative genomic hybridization (CGH), or the more recent array CGH; digital karyotyping provides an evaluation of copy number of genetic material at higher resolution. Digital karyotyping has therefore promised to enhance our understanding of the cancer genome. This article provides an overview of digital karyotyping including the principle of the technology and its applications in identifying potential oncogenes and tumor suppressor genes.
Similar content being viewed by others
References
Wang TL, Maierhofer C, Speicher MR, et al. Digital karyotyping. Proc Natl Acad Sci U S A 2002; 99(25): 16156–61
Velculescu VE, Zhang L, Vogelstein B, et al. Serial analysis of gene expression. Science 1995 Oct 20; 270(5235): 484–7
Parrett TJ, Yan H. Digital karyotyping technology: exploring the cancer genome. Expert Rev Mol Diagn 2005 Nov; 5(6): 917–25
Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006 Feb; 7(2): 85–97
Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005 Sep 15; 437(7057): 376–80
Shendure J, Porreca GJ, Reppas NB, et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 2005 Sep 9; 309(5741): 1728–32
The Cancer Genome Anatomy Project. Digital karyotyping data viewer [online]. Available from URL: http://cgap-stage.nci.nih.gov/SAGE/DKViewHome [Accessed 2006 Jun 9]
Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005 Aug; 37(8): 899–905
Hahn SA, Hoque AT, Moskaluk CA, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996 Feb 1; 56(3): 490–4
Schutte M, da Costa LT, Hahn SA, et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci U S A 1995 Jun 20; 92(13): 5950–4
Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994 Apr 15; 264(5157): 436–40
Teng DH, Perry WL, Hogan JK, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997 Oct 1; 57(19): 4177–82
Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998 Jun 1; 58(11): 2339–42
Nakayama K, Nakayama N, Davidson B, et al. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther 2006 Jun 9, 5 (6) Epub ahead of print
Boon K, Eberhart CG, Riggins GJ. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res 2005 Feb 1; 65(3): 703–7
Di C, Liao S, Adamson DC, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005 Feb 1; 65(3): 919–24
Shih IeM, Sheu JJ, Santillan A, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A 2005 Sep 27; 102(39): 14004–9
Wang TL, Diaz LA, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 2004 Mar 2; 101(9): 3089–94
Acknowledgements
This study was supported by the US Department of Defense grant (W81XWH-05-1-0004).
The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
1. Method for Table I and Table II
In order to identify DNA copy number alterations, we slide a window along each chromosome, looking for places where the sum of tag counts within a window is higher or lower than expected by chance alone. If we assume that the tag counts have a Poisson distribution, then the sum has a Poisson distribution as well, and we can perform hypothesis tests based on that distribution. If the Poisson assumption is correct, these tests are equivalent to the permutation tests usually used for analysis of digital karyotyping data. As shown in table I, we compared the results produced by Poisson test with the results from Monte Carlo simulation in the original digital karyotyping paper.[1] They appear consistent when requiring the PPV to be >95%. We include a p-value adjustment for the multiple tests that arise when scanning the genome and the exact value was determined by extensive simulation.
If there is exactly one mutation on a chromosome, the PPV can be approximated as power/(α + power), where a represents a type I error. We set power to be 0.95 and a to be 0.05, so the PPV will be approximately 0.95 in each cell of the table. More mutations will lead to a higher PPV, so this is in some sense, the most stringent criteria. The calculation was based on a total of 842 202 virtual tags deduced from the entire human genome, and for convenience, an ‘average’ chromosome of 40 000 tags were used for all the calculations, although results may vary slightly between chromosomes of different lengths.
Rights and permissions
About this article
Cite this article
Salani, R., Chang, CL., Cope, L. et al. Digital Karyotyping. Mol Diag Ther 10, 231–237 (2006). https://doi.org/10.1007/BF03256461
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256461